Clinical research firm ICON's Q2 revenue rises 1.2%, beats analyst estimates

Overview

• Clinical research firm's Q2 revenue rose 1.2% yr/yr, beating analyst expectations

• Adjusted EPS for Q2 beat analyst expectations

• Company reaffirmed 2026 full-year revenue and adjusted EPS guidance

Outlook

• ICON reaffirms 2026 revenue guidance of $7.85 bln to $8.15 bln

• Company maintains 2026 adjusted diluted EPS outlook of $10.00 to $11.00

• Company says second-half performance may vary due to pass-through activity

Result Drivers

• COST MANAGEMENT - Co said disciplined cost management offset anticipated operational headwinds, per CEO Barry Balfe

• PASS-THROUGH ACTIVITY - Higher pass-through activity contributed to revenue and net bookings, according to CEO Barry Balfe

• STRATEGIC WINS - Strong strategic wins and new customer acquisition supported book-to-bill ratio, per CEO Barry Balfe

Company press release: ID:nBw4yqPWja

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology medical research peer group is "buy"

• Wall Street's median 12-month price target for ICON PLC is $188.00, about 4.3% above its July 28 closing price of $180.24

• The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads

• July 28 - IQVIA Q2 revenue beats estimates; outlook raised

• July 29 - Fortrea Q2 revenue beats expectations, outlook raised

• July 27 - AstraZeneca Q2 revenue rises 6% on demand for its cancer therapies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)